Research programme: cystic fibrosis therapeutics - Vertex Pharmaceuicals
Alternative Names: cystic fibrosis therapeutics - Vertex PharmaceuicalsLatest Information Update: 06 Sep 2023
At a glance
- Originator Vertex Pharmaceuticals
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cystic fibrosis
Most Recent Events
- 18 Jul 2023 Early research in Cystic fibrosis in USA (unspecified route), prior to July 2023 (Vertex Pharmaceuticals pipeline, July 2023)